Precision Medicine Breast Cancer Registry Launched

September 1, 2015
Precision Medicine Breast Cancer Registry Launched
The primary goal of the Paradigm Registry is to accelerate tumor profiling based on disease biology. [iStock/LilliDay]

Paradigm and TME Research launched the Paradigm Neoadjuvant Breast Registry. The system will use Paradigm’s PCDx next-generation sequencing test and other advanced molecular capabilities to genomically characterize invasive breast cancer patients for targeted neoadjuvant therapies [presurgical treatment]. With more accurate accounts of individual gene variability driving disease, therapy selection will be refined for patient success, according to officials at Paradigm.

The initial six-month pilot for this project will enroll 100 patients across eight primary U.S. centers, potentially expanding to 1,000 patients across 50 U.S. centers. Patients enrolled into the Paradigm Registry will have neoadjuvant chemotherapy or hormone therapy. The patient’s cancer will undergo tumor profiling with the Paradigm platform. 

Precision oncology is an emerging approach for cancer treatment utilized mainly in the metastatic setting but with great potential to direct initial therapy, said Robert J. Penny M.D., Ph.D., CEO of Paradigm. The primary goal of the Paradigm Registry is to accelerate tumor profiling based on disease biology so that relevant neoadjuvant clinical trials and/or refined treatment regimens can be identified particularly when competing options exist.

For the rest of the story, click here.

×

Oops! Please type your email in the following format: [email protected]

You’re all set!
Thank you for subscribing to
Clinical OMICs Weekly
.